Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Reproduction of any article requires authorization.
May 20,NEUREGEN Announces Completion of Series A FinancingThis A-round financing was led by Wuhan Optics Valley Sci-Tech Innovation Industry Investment Fund Partnership (Limited Partnership) and followed by Zhuhai Hengqin SoftBank Xinchuang Equity Investment Management Enterprise (Limited Partnership).The funds will be mainly used for the advancement of core pipeline clinical trials, preclinical research and development of other pipelines, and the continuous iteration of the in-situ transdifferentiation technology platform.Including the previously completed Pre-A+ round of financing (with additional investments from existing shareholders Linchuang Sinan and Shanghai Science Investment)., the company completed financing of nearly 100 million RMB in 2025, which strongly supported and ensured the company's development strategy of "proceeding steadily and safely entering the fast lane."
NEUREGEN has laid out multiple innovative product pipelines in the fields of oncology, ophthalmology, and neurodegenerative diseases, which have significant unmet clinical needs, based on its original and globally leading in situ transdifferentiation (in vivo cell reprogramming) technology platform.NRG-103 Injection is developed by NEUREGEN based on its proprietary in situ transdifferentiation technology (also known as in vivo cell reprogramming innovation technology), leveraging its globally leading transdifferentiation factor screening and optimization platform and viral vector development and optimization platform.Combining Transdifferentiation Technology with Tumor ImmunotherapyAn innovative product developed for the treatment of glioblastoma. This product not only exhibits excellent tumor cell killing ability but also transforms glioma stem cells, which are insensitive to chemotherapy and immunotherapy, or glioma cells that have developed drug resistance, into non-proliferating cells through transdifferentiation. By effectively eliminating the cellular source of tumor recurrence, it addresses the clinical challenge of high recurrence in glioblastoma at its root, with the potential to significantly extend survival.Among them,NRG-103It has successively obtained clinical trial approval (IND) from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, orphan drug designation (ODD) and clinical trial application (IND) approval from the U.S. Food and Drug Administration (FDA), and has entered Phase I clinical trials for registration in China. It is a truly innovative drug originating from Chinese science and recognized as a world-first (FIC) investigational drug.As the company enters a fast track of development, it will continuously push forward and expand in core dimensions such as technological iteration, core product R&D, overseas expansion and BD collaboration, and ongoing financing with increasing efforts. This will further strengthen NEUREGEN's technological, capital, and operational capabilities in the global cutting-edge fields of oncology and neurological disease treatment. The aim is to accelerate the productization and industrialization of various innovative therapies, thereby benefiting patients worldwide, rewarding shareholders, and bringing value to society.NEUREGEN is a biotechnology company that aims to develop FIC innovative drugs by utilizing its proprietary in-situ transdifferentiation (in vivo cell reprogramming) technology. The company is committed to providing patients with new therapeutic products and solutions through the technical approach of "precisely reprogramming cells within the diseased microenvironment in vivo." Founded by senior experts from the fields of neurobiology, oncology, ophthalmology, and the biopharmaceutical industry, the company’s first-phase product pipeline focuses on neurological tumors and degenerative diseases. It emphasizes the development of original treatments for blinding eye diseases, other degenerative conditions, and difficult-to-treat neurological tumors. In the future, the applications can be expanded to include a broader range of therapeutic areas, such as diseases of other tissues and organs, as well as anti-aging treatments.Source of the article:NEUREGEN
Mastering CAR-T Therapy, Stem Cell Therapy, GeneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
